Generic drug freedom-to-operate is not a legal checklist—it’s a strategy.
In the patent world, the “picket fence” is the familiar barrier: a thicket of patents that can block entry, delay launches, and turn a launch calendar into a negotiation calend…

Drug patents in Africa: exactly how long they last—and why it matters more than most people think
The hook: If you’re investing in medicines across Africa, you’re not just underwriting demand—you’re underwriting time. And time, in pharma, is often dete…

🚦 Green light for FTO: the definitive step-by-step guide is here—and it changes how new drug products should think about “freedom to operate.”
In pharma, the most expensive word isn’t “trial.” It’s “infringement.”
For teams building a new drug pro…

Biotech investors don’t lose money because they can’t read the science. They lose money because they overpay for the wrong signals.
Here’s the uncomfortable truth: most “value” frameworks in biotech are built on narratives—platform potential, pipeline …

Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System (Explained)
In pharma, “protection” isn’t one thing—it’s two.
And if you’re an investor, a policy watcher, a competitor, or even a brand team trying to forecast launch t…

First-to-File, First-to-Profit: The Quiet Power of Paragraph IV and 180-Day Exclusivity
In generic drug competition, speed isn’t just a competitive advantage—it can be a business model.
A lot of people talk about “patent challenges” like they’re purely…

Generic and biosimilar timing isn’t a guess—it’s a discipline.
If you’re managing formularies, contracts, or patient access, you’ve probably felt the pressure: a brand’s “exclusivity” is expiring, competitors are circling, and internal stakeholders w…

Before a drug ever hits a press release, the real competition is already in motion.
Most teams only react once a pipeline is public—when a company files a press release, posts trial results, or publishes a slide deck. But in pharma, “public” is often…

20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
Most people think drug patent life is a simple countdown: 20 years from filing. In reality, the clock is more like a relay race—multiple “start times,” multiple legal events…

Pick the Right Patent—or Leave Billions on the Table: The One-Patent-Per-Product Rule and PTE Selection Strategy
In pharma, the difference between winning and losing often isn’t science—it’s paperwork, timing, and precision.
A single misstep in patent …